恩替卡韦治疗慢性乙型病毒YMDD自然变异临床疗效

Entecavir effect on the chronic hepatitis patients with hepatitis B virus YMDD mutationl

目的观察恩替卡韦治疗慢性乙型肝炎病毒YMDD自然变异临床疗效疗效和安全性。方法选择YMDD自然变异患者65例，随机分为对照组和治疗组，对照组予拉米夫定100mg／d口服治疗、治疗组予恩替卡韦1mg／d口服治疗，疗程48周。结果对照组患者在前12周ALT和HBVDNA水平下降显著下降，但在24周后有所反弹；B组在第4周时，ALT升高明显，此后呈下降趋势，在治疗48周后ALT水平和HBVDNA水平与A组比较有显著性差异（P〈0．05），ALT复常率、HBVDNA转阴率与A组比较具有差异（P〈0．05）。结论恩替卡韦治疗慢性乙型病毒YMDD自然变异患者具有良好的疗效和安全性。

Objective To explore the efficacy and safety of Entecavir effect on the chronic hepatitis patients with hepatitis B virus YMDD mutationl. Methods The 65 chronic hepatitis B virus YMDD mutationl patients were randomly divided into two groups：The treatment group and the control, The patients in control received lamivudineat therapy at a dose of 100 mg daily ;however the patients in treatment group received Entecavir therapy at a dose of 1 mg daily, and the course of treatment was 48 weeks. Results Duiring the first 12 weeks, the control group＇ s ALT and HBV DNA level decreased,while after the 24th week,it incredsed a little. The treatment group＇ s ALT level incredsed significtly at 4th week and then it declined from then on. The number of patients in treatment group whose ALT level came down to mormal and HBV DNA level turned into negative in the treatment group were biger than that of group B （ P 〈 0. 05 ） at 48th week. Conclusion Entecavir is effective and safe for the chronic hepatitis patients with hepatitis B virus YMDD mutationl.